Drug pricing

Navitus Health Solutions Launches Program to Help Members Overcome Challenges Along the Prescription Journey

Retrieved on: 
Friday, January 15, 2021
Managed care, Pharmaceutical, Health, Health sciences, Pharmacy, Health care, Health, Symbols, Clinical pharmacology, Drug pricing, Pharmaceutical industry, Pharmacy benefit management, Medical prescription, Academic detailing, Medication costs

This three-pronged solution consists of Medication Therapy Management, Academic Detailing and Personalized Member Transitions to help health plans, providers and patients navigate the complex prescription journey.

Key Points: 
  • This three-pronged solution consists of Medication Therapy Management, Academic Detailing and Personalized Member Transitions to help health plans, providers and patients navigate the complex prescription journey.
  • Members face a number of crossroads along their healthcare journey, said Dr. Julie Olson, senior director of population health programs and product development at Navitus.
  • With Navitus new Clinical Engagement Center, were able to deliver personalized clinical support while mitigating ancillary prescription costs.
  • Navitus Health Solutions, a division of SSM Health and Costco Wholesale Corporation, serves as a full pass-through pharmacy benefit manager (PBM) and industry alternative to traditional models.

Nevada Shelves Program Cuts in Victory for HIV Patients: Federal 340B Changes Forestalled

Retrieved on: 
Thursday, January 14, 2021
AIDS, White House, Federal Government, Public policy, Government, Health, State, Local, Infectious diseases, Health Resources and Services Administration, 340B Drug Pricing Program, Drug pricing

This delay will allow DPBH additional time to review the impact of community partners using the federal 340B program and the program income received directly to them and the impact of rebate revenue received at NMAP.

Key Points: 
  • This delay will allow DPBH additional time to review the impact of community partners using the federal 340B program and the program income received directly to them and the impact of rebate revenue received at NMAP.
  • After Nevada health officials first announced the plan, many community partners and nonprofit HIV providers decried the states action, warning it could have a profound and negative impact on patient care.
  • The 340B program, which costs taxpayers nothing, allows Ryan White HIV Clinics and providers to acquire HIV drugs at a steep discount, using the savings from those discounts to pay for HIV services not covered by their Ryan White grants.
  • Some of the advocates and HIV providers also ran an advocacy ad ( 340B ad ) targeting Nevada health officials and legislators urging state officials to not to interfere with the states successful 340B program.

EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

Retrieved on: 
Monday, January 11, 2021
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Health, Pharmaceutical industry, Life sciences, Pharmacy, Drug pricing, Medication, Health system

EQRx , a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing.

Key Points: 
  • EQRx , a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing.
  • With this Series B financing, EQRx is well-poised to make sustainable drug pricing a reality for people, payers and health systems.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.
  • EQRx and Remaking Medicine are trademarks of EQRx, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005320/en/

AHF Thanks HHS for Clarifying Rules on 340B Drug Pricing; Blasts Pharma’s Greed

Retrieved on: 
Wednesday, December 30, 2020
White House, Federal Government, Public policy, Other Health, Other Policy Issues, Healthcare reform, Pharmaceutical, Practice Management, General Health, Philanthropy, Congressional News, Views, Hospitals, Public policy, Government, Foundation, AIDS, Health, Drug pricing

What the pharmaceutical drug companies are doing here is absolutely unconscionable and unacceptable, Blumenthal said.

Key Points: 
  • What the pharmaceutical drug companies are doing here is absolutely unconscionable and unacceptable, Blumenthal said.
  • We thank HHS for really listening to safety net providers, the attorneys general and others in recognizingand checkingthe unbridled greed of the pharmaceutical industry.
  • Instead, they chose to break their contractual obligations underlining their participation in 340B and have now been taken to task by HHS.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare .

AHF to Protest Amgen Over Unlawful Drug Restrictions

Retrieved on: 
Monday, December 21, 2020
Medical Supplies, Congressional News, Views, Public policy, Government, White House, Federal Government, AIDS, State, Local, General Health, Pharmaceutical, Health, Public policy, Health Resources and Services Administration, United States Department of Health and Human Services, Health department, Health care in the United States, Drug pricing, 340B Drug Pricing Program, United States, AIDS Healthcare Foundation

They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.

Key Points: 
  • They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.
  • The rapacious greed of Amgen is limitless, said John Hassell, national director of advocacy for AHF.
  • AHF calls on the U.S. Department of Health and Human Services ( HHS ) to do its job and stop this callous drug industry attack on the U.S. healthcare safety net.
  • Its a social justice imperative for the new administration to protect the 340B Drug Discount Program.

AHF to HRSA: Reject Kalderos’ Plan to Hurt 340B Drug Discount Program

Retrieved on: 
Monday, December 21, 2020
Other Government, Infectious diseases, Congressional News, Views, Public policy, Government, AIDS, Health, Pharmaceutical, Public policy, Other Policy Issues, Health Resources and Services Administration, Pricing, Rebate, Sales promotion, Drug pricing, 340B Drug Pricing Program

The Kalderos plan would convert the 340B Drug Price Program from a discount to a rebate program and would set Kalderos up as the arbiter of who will get the rebate and when, putting the fox in charge of the henhouse, said Tom Myers, AHF chief of public affairs and general counsel.

Key Points: 
  • The Kalderos plan would convert the 340B Drug Price Program from a discount to a rebate program and would set Kalderos up as the arbiter of who will get the rebate and when, putting the fox in charge of the henhouse, said Tom Myers, AHF chief of public affairs and general counsel.
  • Under the 340B statute, drug manufacturers are required to sell drugs to safety net providers at or below the discount price.
  • Congress intentionally expanded the 340B program with the full knowledge and explicit approval of the drug industry.
  • AHF urges the U.S. Health Resources and Services Administration which runs the 340B to assert its authority as enforcer of the 340B program and reject the Kalderos steal, concluded Myers.

Kalderos upgrades 340B Pay platform, giving covered entities more options

Retrieved on: 
Tuesday, December 15, 2020
Health Resources and Services Administration, Drug pricing, 340B Drug Pricing Program, Healthcare reform in the United States, Rebate, Medicaid

CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Drug Discount Management company Kalderos today announced a significant upgrade to its 340B Pay solution that gives covered entities more choice in how they realize the benefits of the 340B program.

Key Points: 
  • CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Drug Discount Management company Kalderos today announced a significant upgrade to its 340B Pay solution that gives covered entities more choice in how they realize the benefits of the 340B program.
  • The solution enables manufacturers, covered entities and Medicaid agencies to work together to effectuate 340B discounts compliantly and efficiently.
  • 340B Pay, and its tools, Request and Verify, allow providers of any size to request 340B rebates and manufacturers to verify and pay them through a third party payment partner.
  • With 340B rebate funds from contract pharmacy dispenses flowing directly to covered entities, covered entities will benefit from greater control over program savings, enabling them to better serve patients.

28 State AGs Demand HHS Sec. Azar Enforce Laws on 340B Drug Pricing

Retrieved on: 
Tuesday, December 15, 2020
Managed care, General Health, Pharmaceutical, White House, Federal Government, State, Local, Infectious diseases, Public policy, Other Policy Issues, Medical Supplies, AIDS, Health, Public policy, Government, Health Resources and Services Administration, Drug pricing, 340B Drug Pricing Program, Health sciences, United States Department of Health and Human Services, United States federal executive departments, AIDS Healthcare Foundation, Alex Azar, Azar, Pharmaceutical industry, Healthcare Systems Bureau

AIDS Healthcare Foundation ( AHF ) praised 28 U.S. state attorneys general who have drawn a line in the sand to protect an essential part of the healthcare safety net: the 340B Drug Pricing Program against the limitless greed of the drug industry.

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) praised 28 U.S. state attorneys general who have drawn a line in the sand to protect an essential part of the healthcare safety net: the 340B Drug Pricing Program against the limitless greed of the drug industry.
  • In their December 14 letter , the bipartisan group of elected attorneys general demand that U.S. Health and Human Services ( HHS ) Secretary Alex Azar take immediate steps to enforce the law to address drug companies unlawful refusal to provide critical drug discounts to covered entities such as community health centers under the 340B Drug Pricing Program.
  • View the full release here: https://www.businesswire.com/news/home/20201214005885/en/
    Letter to HHS Secretary Alex Azar from 28 state AGs demanding that he enforce the law on 340B drug pricing as required by section 340B of the U.S. Health Services Act.
  • AHF has repeatedly criticized these nine drug companies whose actions the AGs are calling unlawful.

AHF Blasts Amgen Over Drug Restrictions; Asks Biden Administration to Sanction It and Others

Retrieved on: 
Thursday, December 10, 2020
AIDS, White House, Federal Government, Public policy, Government, Healthcare reform, Health, Pharmaceutical, Health Resources and Services Administration, Pharmaceutical industry, Pharmacology, Pharmacy, Drug pricing, 340B Drug Pricing Program

The U.S. government already gives special favors to drug companies to produce expensive orphaned drugs for rare diseases that would otherwise be unaffordable.

Key Points: 
  • The U.S. government already gives special favors to drug companies to produce expensive orphaned drugs for rare diseases that would otherwise be unaffordable.
  • They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.
  • Its a social justice imperative for the new administration to protect the 340B Drug Discount Program.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare .

Are Americans Ready for Increased Health Care Costs Next Year?

Retrieved on: 
Thursday, December 10, 2020
Health sciences, Health, Pharmacy, Pharmaceuticals policy, Drug pricing, Clinical pharmacology, Drugs, Prescription drug, Medication costs, Health care in the United States, Healthcare in Canada

Nearly three in five (58%) say they would be financially prepared to afford the cost of their health care if it were to increase in January 2021.

Key Points: 
  • Nearly three in five (58%) say they would be financially prepared to afford the cost of their health care if it were to increase in January 2021.
  • This increased concern around their health may be why nearly one in five (18%) have done more research on health care or prescription medication costs - one of the biggest fluctuating costs for most consumers - now more than ever.
  • "As more Americans plan for rising prescription costs in 2021, RxSaver remains focused on our mission of making health care affordable," said Kim Read, Senior Vice President and General Manager of RxSaver.
  • RxSaver is utilizing this survey data to better serve Americans as they manage both personal health and financial changes.